HalleMBinzenhöferLMahrholdtH, et al. Myocarditis in athletes – a clinical perspective. Eur J Prev Cardiol, Epub ahead of print 3 March 2020. DOI: 10.1177/2047487320909670
2.
EichhornCBièreLSchnellF, et al. Myocarditis in athletes is a challenge: Diagnosis, risk stratification, and uncertainties. JACC Cardiovasc Imaging 2020; 13: 494–507.
3.
MaronBJThompsonPDAckermanMJ, et al.
Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: A scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation2007;
115: 1643–1655.
4.
SheikhNPapadakisMGhaniS, et al.
Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite Black and White athletes. Circulation2014;
129: 1637–1649.
ShaveRBaggishAGeorgeK, et al.
Exercise-induced cardiac troponin elevation: Evidence, mechanisms, and implications. J Am Coll Cardiol2010;
56: 169–176.
7.
NeilanTGJanuzziJLLee-LewandrowskiE, et al.
Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation2006;
114: 2325–2333.
8.
AbergelEChatellierGHagegeAA, et al.
Serial left ventricular adaptations in world-class professional cyclists: Implications for disease screening and follow-up. J Am Coll Cardiol2004;
44: 144–149.
9.
La GercheARakhitDJClaessenG.Exercise and the right ventricle: A potential Achilles’ heel. Cardiovasc Res2017;
113: 1499–1508.
10.
PellicciaASolbergEEPapadakisM, et al.
Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: Position statement of the Sport Cardiology Section of the European Association Of Preventive Cardiology (EAPC). Eur Heart J2019;
40: 19–33.
11.
MaronBJUdelsonJEBonowRO, et al.
Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: A scientific statement from the American Heart Association and American College of Cardiology. Circulation2015;
132: e273–e280.
